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Abstract 
Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that 
bind in an allosteric binding pocket in HIV-1 RT, located about 10 Å from the polymerase active site. Binding of an 
NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, pre-
venting viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 
drugs, suboptimal treatment can lead to the development of resistance. To generate better compounds that could be 
added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants 
that are resistant to the available NNRTIs.
Results: Using a single-round infection assay, we identified several RPV analogs that potently inhibited a broad 
panel of NNRTI resistant mutants. Additionally, we determined that several resistant mutants selected by either RPV 
or Doravirine (DOR) caused only a small increase in susceptibility to the most promising RPV analogs.
Conclusions: The antiviral data suggested that there are RPV analogs that could be candidates for further develop-
ment as NNRTIs, and one of the most promising compounds was modeled in the NNRTI binding pocket. This model 
can be used to explain why this compound is broadly effective against the panel of NNRTI resistance mutants.
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Background
HIV-1 reverse transcriptase (RT) is a target for many 
drugs used in highly active antiretroviral therapy 
(HAART) to treat HIV-1 infections [1]. RT has two enzy-
matic activities: (1) a DNA polymerase that can copy 
either an RNA or a DNA template and (2) an RNase H 
that degrades RNA if and only if the RNA is part of a 
RNA: DNA hybrid. Although there are, as yet, no drugs 
that target the RNase H of HIV-1 RT, there are two classes 
of drugs that target the DNA polymerase. The first class 
consists of inhibitors that are analogs of normal nucleo-
sides used to synthesize DNA (nucleoside reverse tran-
scriptase inhibitors, NRTIs). All of the FDA-approved 
NRTIs lack the 3′ –OH present on the deoxyribose of 
normal nucleosides. When an NRTI is incorporated into 
the growing viral DNA strand, it acts as a chain termi-
nator. The second class consists of inhibitors that bind 
in a small hydrophobic pocket ~10  Å from the poly-
merase active site (non-nucleoside reverse transcriptase 
inhibitors, NNRTIs) [2–4]. The NNRTI binding pocket is 
closed in the absence of a bound NNRTI [5]. The NNRTI 
binding pocket is formed by the following residues: L100, 
K101, K103, V106, V179, Y181, Y188, G190, F227, W229, 
L234, P236, and Y318. The binding pocket lies under-
neath the bound double-stranded nucleic acid substrate. 
Binding of an NNRTI distorts RT, which affects the align-
ment of the primer terminus and the polymerase active 
site, blocking the chemical step of viral DNA synthesis 
[6–8]. There currently are sixteen drugs that target RT 
that have been approved by the FDA for the treatment of 
HIV-1 infections; eleven are NRTIs and five are NNRTIs. 
The five approved NNRTI drugs are: nevirapine (NVP, 
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Viramune), delavirdine (DLV, Rescriptor), efavirenz 
(EFV, Sustiva), etravirine (ETR, Intelence), and rilpiv-
irine (RPV, Endurant,). While NNRTIs effectively block 
the replication of WT HIV-1, NNRTI-resistant mutants 
can emerge during treatment, many of which cause 
cross-resistance among the approved NNRTIs.
There are two primary factors that contribute to the 
emergence of resistance to NNRTIs: (1) HIV-1 RT can 
tolerate a wide range of sequences in and around the 
NNRTI binding pocket and (2) there is extensive HIV-1 
genetic variation [9, 10]. Although most HIV-infected 
individuals are initially infected with a single virion, 
HIV-1 variants arise rapidly due to high viral loads in 
HIV-1 infected patients, which leads to the infection 
of large numbers of cells, the rapid turnover of these 
infected cells, and to errors made during HIV-1 replica-
tion [10–12]. Ultimately, error prone replication creates 
the mutations that enable HIV-1 to develop resistance 
against antiretroviral drugs.
A number of drug resistant mutants were selected in 
HIV-infected individuals by the first generation NNRTIs 
(NVP, EFV, and DLV). Resistance mutations are com-
monly seen in the residues that surround the NNRTI 
binding pocket, including: L100I, K103N, V106A, Y181C, 
Y188L, and H221Y. These mutations alter the geom-
etry of the NNRTI binding pocket in ways that inter-
fere with the binding of NNRTIs. The first generation 
inhibitors were rigid and bulky compounds that were 
particularly vulnerable to the effects of resistance muta-
tions. The second generation NNRTIs, ETR and RPV, 
were designed to be less bulky and more flexible, and are 
better able to adapt to the changes in the NNRTI bind-
ing pocket caused by resistance mutations. This allows 
these newer NNRTIs to effectively inhibit both WT 
HIV-1 and a number of drug resistant variants [13, 14]. 
However, when these drugs were tested in clinical trials, 
patients who were on an ETR containing regimen were 
found to have a combination of mutations including: 
V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/
I/V, and G190A/S [15]. A variety of mutations including 
K101E/P, E138A/G/K/Q/R, Y181C/I/V, and M230L have 
been shown to be associated with a decrease in suscepti-
bility to RPV and have been detected in clinical samples 
from HIV-1-infected individuals treated with RPV [16]. 
Individuals who failed in a clinical trial involving therapy 
with RPV and NRTIs had mutations at positions E138K 
and M184I/V; the M184V mutation was likely selected by 
FTC, an NRTI often included in HAART regimens [17, 
18].
Because development of resistance can occur with 
all of the available NNRTIs, there are ongoing efforts 
to develop NNRTIs that extend and improve the effec-
tiveness of the previously identified compounds. For 
example, doravirine (DOR) is a new NNRTI in late stage 
clinical trials [19]. Although it selects for resistance, the 
mutations that reduce the potency of DOR do not, for 
the most part, overlap with mutations that reduce the 
potency of RPV [20]. As an alternative approach, we are 
testing whether RPV analogs have better resistance pro-
files than the parent compound.
Several of our RPV analogs are broadly effective against 
HIV-1 mutants. One compound (11) was particularly 
effective in inhibiting the replication of mutants that have 
reduced susceptibility to RPV and DOR, suggesting that 
it has the potential to become a clinically useful NNRTI.
Results and discussion
Susceptibility of mutant HIV‑1 to RPV analogs
We previously determined the ability of several of 
our RPV analogs to inhibit infection of WT HIV-1 or 
mutants that contain several well-known NNRTI-resist-
ant mutations (L100I, K103N, E138K, Y181C, Y188L, 
H221Y, and K103N/Y181C) using a single-round infec-
tion luciferase assay [21]. As shown in Figs.  3 and 4 of 
that aforementioned study, RPV and several analogs (6, 
7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 21, and 27) had potent 
antiviral activities against both WT HIV-1 and several of 
the resistant mutants L100I, K103N, Y181C, and H221Y 
(all IC50s < 7 nM). The E138K mutant caused only a small 
drop in the IC50s for most of the compounds (<5  nM); 
however there was a greater loss in susceptibility to 12 
(15 nM ± 1.2). The resistant mutant Y188L showed mod-
est drop in susceptibility to 8, 9, 11, 12, 14, 15, 16, and 
17 (IC50s ranged from 12 to 64 nM), whereas compounds 
6, 7, 13, 21, and 27 showed a modest loss of potency 
against this resistant mutant (all <10  nM). The NNRTI 
resistant double mutant K103N/Y181C caused a sub-
stantial decrease in susceptibility to RPV analogs 6, 8, 9, 
13, 21, and 27 (ranged from 25 to 100 nM), whereas this 
mutant caused a minor loss in susceptibility to RPV, 7, 
11, and 13 (<5 nM).
Because several of our RPV analogs were active against 
the first set of NNRTI resistant mutants, we tested the 
antiviral activities of RPV and the most promising ana-
logs 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 21, 26, and 27 
against a much broader panel of resistant mutants. These 
compounds are structural homologs of RPV (Fig. 1) that 
have the following differences: the addition of an exocy-
clic moiety at position 5 (6, 7) or the central pyrimidine 
moiety is in a “flipped” conformation relative to RPV 
(8,9), a substitution of the central pyrimidine ring with 
a 2,6-purine ring system (11) or this same 2,6-purine 
ring system in the “flipped” conformation with or with-
out a protecting group (12, 13) or this same 2,6-purine 
ring system with additional modifications on the benzyl 
moiety (14, 15, 16, 17, 21), or a substitution of central 
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pyrimidine ring with a 2,9-purine ring system (27) or this 
ring system in a “flipped” orientation (26).
To determine the ability of these RPV analogs to 
inhibit a wider range of NNRTI mutants, we tested 
their antiviral activity in a single-round infectivity assay 
against: G190A, G190S, M230L, P236L, L100I/K103N, 
K103N/P225H, and V106A/G190A/F227L (Fig. 2; Addi-
tional file 1: Table S1). Compound 26, which has a cen-
tral 2,9-purine ring system in the “flipped” orientation, 
had poor activities in the initial study and was included 
with the more promising compounds to see if there was 
obvious complementarity in terms of which mutants the 
compounds would inhibit. RPV and the analogs 6, 7, 8, 
9, 11, 12, 13, 14, 15, 16, 17, 21, 26, and 27 all potently 
inhibited the replication of WT HIV-1. The IC50 values 
in the single round assay were, for the most part, low 
nanomolar against the WT (all <2.2 nM; except for 26, 
which was 7.7 nM ± 2.3), and against several of the RT 
mutants: G190A (all <1.6 nM; except for 26, which was 
2.2 nM ± 0.71), G190S (all <1 nM; except for 26, which 
was 2.1  nM  ±  0.2), P236L RT (all <1.7  nM; except for 
26, which was 2.91 nM ± 0.007), and K103N/P225H (all 
8 6 7 RPV 9 
11 13 12 14 15 
16 17 21 26 27 
Fig. 1 Chemical Structures of the RPV Analogs. Chemical structures of RPV and the RPV analogs. The parts of the analogs that differ from RPV are 
indicated in red
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<4.6  nM; except for 26, which was 12.9  nM ±  3.3). In 
the crystal structure of HIV-1 RT bound to RPV, posi-
tion 190 is located at the back of the NNRTI binding 
pocket and is >6 Å away from RPV. When we modeled 
the binding of the RPV analogs in the NNRTI bind-
ing pocket, the distances of the compounds to position 
190 were similar to RPV (Figs.  6, 7), which explains 
why mutations at 190 do not interfere with the binding 
of this family of inhibitors. The models show that the 
RPV analogs are 3–4 Å from amino acids 225 and 236, 
which reside in the depths of the NNRTI binding pocket 
(Figs. 6, 7). HIV-1 containing the M230L mutation was 
susceptible to RPV and to the analogs 6, 7, 11, 13, 14, 
16, 21, and 27 (all IC50s < 6.1 nM), but showed a modest 
decrease in susceptibility to analogs 8 (11.9 nM ± 1.1), 9 
(29.6 nM ± 1.1), 12 (13.8 nM ± 7.1), 15 (16.8 nM ± 1.4), 
and 17 (21.1  nM  ±  8.8), while compound 26 was not 
effective in our assay (IC50 > 100 nM, above the limit of 
detection in our assay). The antiviral results suggest that 
most of the RPV analogs with a central purine scaffold 
and a benzonitrile moiety identical to the one on RPV, 
or a similar moiety that lacks the fluoride modification, 
can successfully inhibit viruses with the M230L muta-
tion in RT. RPV analogs with modifications at position 
5 on the pyrimidine scaffold, with the scaffold in the 
same orientation as RPV, are also capable of inhibiting 
the M230L variant. The NNRTI resistant double mutant 
L100I/K103N posed a problem for some of the RPV 
analogs. Both compounds 14 (12.6  nM  ±  1.6) and 15 
(15.5  nM ±  .6) showed minor reductions in sensitivity 
to L100I/K103N, while compounds 9 (44.1 nM ± 17.6), 
17 (63.4  nM  ±  12.6), 21 (37.6  nM  ±  0.14), and 27 
(39.8  nM  ±  9.2) had a significant drop in sensitivity 
and 26 was beyond the limits of detection using our 
assay (>100  nM). However, RPV and analogs 6, 7, 8, 
11, 12, 13, and 16, showed strong antiviral activities (all 
<5.4  nM) against L100I/K103N. These data illustrate 
the importance of preserving the benzonitrile group as 
one of the arylamines. The problems associated with the 
K103N mutation might restrict the range of functional 
groups on the inhibitors that can be used at this position 
[22].
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Fig. 2 Antiviral activities of RPV and the RPV analogs against well-characterized NNRTI resistant mutants. The IC50 values of RPV and the RPV ana-
logs were determined using a vector that carries WT RT and several well-known NNRTI resistant mutants in a single round infection assay. Error bars 
represent thestandard deviations of independent experiments, n = 4. The IC50 values of the graph are at a maximum value of 100 nM and the IC50 
value of 26 against the M230L and L100I/K103N resistant mutants was beyond the point of detection in our single round infection assay, >100 nM. 
To better illustrate the lower IC50 values, the Y-axis is broken from 20 to 40 nM and also shown in the corresponding bars
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Fig. 3 Antiviral Activities of RPV and RPV analogs against mutants selected by DOR in cell culture. RPV and the RPV analogs were tested against 
several mutants selected by DOR in cell culture. The IC50 values for RPV and the RPV analogs were measured using a single round infection assay. 
Error bars represent the standard deviations of independent experiments, n = 4. The IC50 values of the graph are at a maximum value of 100 nM. To 
better illustrate the lower IC50 values, the Y-axis is broken from 10 to 20 nM and also shown in the corresponding bars
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Susceptibility of mutants selected by DOR to inhibition 
by RPV analogs
DOR is a new NNRTI currently undergoing evaluation 
in Phase III clinical trials [19]. DOR was able to inhibit 
the replication of several well-known NNRTI-resistant 
mutants but readily selected resistant mutants in in vitro 
experiments [20]. V106A was the major variant selected 
in  vitro and it was often accompanied by additional 
mutations, such as F227L, L234I, and F227L/L234I. We 
screened a larger panel of NNRTI-resistant mutants for 
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Fig. 4 Antiviral activities of RPV and RPV analogs against mutants selected by RPV. The IC50 values of RPV and the RPV analogs were measured 
against mutants found in RPV-treated patients (K101E, E138K, M184I, M184V, K101E/M184I, K101E/M184V, E138K/M184I, and E138K/M184V) or 
selected by RPV in cell culture (E40K, D67E, and V111A) using a single round infection assay. Error bars represent the standard deviations of inde-
pendent experiments, n = 4. The IC50 values of the graph are at a maximum value of 100 nM. To better illustrate the lower IC50 values, the Y-axis is 
broken from 10 to 20 nM and also shown in the corresponding bars
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their susceptibility to DOR and RPV (unpublished obser-
vations). DOR and RPV appear to differ in their suscep-
tibility to NNRTI resistance mutations. We screened the 
RPV analogs against the mutants that were selected by 
DOR: V106A, 234I, V106A/F227L, V106/L234I, and 
V106A/F227L/L234I (Fig. 3; Additional file 1: Table S2). 
All 5 of these mutants were effectively inhibited by RPV 
and 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 21, and 27 (all 
of the tested compounds had IC50s  <  5  nM except 26; 
7.7 ± 2.3).
Susceptibility of viruses carrying RPV‑resistance mutations 
to the RPV analogs
In individuals who fail RPV-containing regimens, the 
E138K mutation is one of the most common NNRTI-
resistance mutations. The E138K mutation is frequently 
associated with M184V or M184I, which are presumably 
selected by FTC or 3TC, one of which was also present in 
the regimen [23, 24]. K101E is a resistance mutation that 
is commonly selected by RPV and ETR, an NNRTI that 
is related to RPV. In addition, we selected for mutants in 
cell culture by passaging replication competent HIV-1 in 
the presence of 11 and obtained viruses that carry addi-
tional mutations: E40K, D67E, V111A, E138K, Y181C, 
and M230I. The selection of viruses carrying mutations at 
E138K and Y181C was expected because of the contacts 
made between 11 and the residues of the NNRTI bind-
ing pocket; M230I is near the NNRTI binding pocket. 
Thus, these mutations may interfere with the binding of 
11 into the NNRTI binding pocket. The V111A mutation 
is close in proximity to the triad of aspartic acids (D110, 
D185, and D186) that comprise the polymerase active 
site; it is not clear how this mutation could directly affect 
NNRTI binding. Similarly, the mutations at E40K and 
D67E are in the fingers subdomain of RT, distant from 
the NNRTI binding pocket and should not affect NNRTI 
binding. As discussed earlier, we previously measured 
the effects of the Y181C and M230L (which should be 
similar to M230I) mutations on the susceptibility of the 
vector to these compounds [21]. The RT residues E138 in 
the RT p51 subunit and K101 of the RT p66 subunit are 
important because they form a salt bridge at the rim of 
the NNRTI binding pocket and act as “gate-keepers” that 
inhibit the entry of NNRTIs into the pocket [25, 26]. The 
amine linkers of RPV make hydrogen bond contacts with 
the main chain carbonyls of K101 and E138, which help 
to compensate for the loss of the interaction between the 
acidic side chains of these two amino acids when RPV is 
bound in the NNRTI binding pocket [27]. To determine if 
our RPV analogs could inhibit the replication of mutants 
selected in the presence of RPV, we tested RPV and the 
RPV analogs 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 21, 26, 
and 27 for their ability to inhibit the replication of: E40K, 
D67E, K101E, V111A, E138K, M184I, M184V, K101E/
M184I, K101E/M184V, E138K/M184I, and E138K/
M184V (Fig. 4; Additional file 1: Table S3). Although the 
M184I/V mutations should not directly affect the binding 
of an NNRTI, some of the viruses selected in patients in 
trials that included RPV and an NRTI had one of these 
mutations, and we wanted to make sure that the M184I/V 
mutations did not affect the impact of the K101E or 
E138K mutations on the susceptibility of the vector to 
any of the RPV analogs. RPV and the analogs 6, 7, 11, 
13, 14, 16, 21, and 27 potently inhibited the replication 
(<2.5 nM) of E40K, D67E, K101E, V111A, E138K, M184I, 
M184V, K101E/M184I, K101E/M184V, E138K/M184I, 
and E138K/M184V. The RPV analogs 8, 9, and 15 were 
almost as potent (<6 nM) against these mutants, except 
K101E, which was less susceptible to 8 (10.1  nM  ±  4), 
and D67E, which caused a reduction in susceptibility to 
both 8 and 15 (12.7 nM ± 0.2 and 13.1 nM ± 1, respec-
tively). RPV and the analogs 6, 13, 14, and 27 had com-
parable antiviral activities against this set of mutants 
while 11 showed a modestly enhanced susceptibility 
profile. Analog 17 showed consistently lower poten-
cies against E40K (6.4 nM ± 0.8), D67E (26 nM ± 0.07), 
K101E (8.9  nM ±  0.07), E138K (13.5  nM ±  4), K101E/
M184I (15 nM ± 4.9), and K101E/M184V (8.1 nM ± 2.5). 
The D67E mutation caused a decrease in susceptibility to 
the some of the RPV analogs 8, 12, 15, and 17, which is 
surprising, because, as mentioned earlier, this mutation is 
not in or near the NNRTI binding pocket. Analog 26 was 
relatively ineffective against this set of mutants. Overall, 
it seems that either a pyrimidine or purine is acceptable 
as a central scaffold as long as amine linkers are present 
that can interact with K101 of the p66 subunit and E138 
of the p51 subunit.
In addition to the E138K resistance pathway, there 
is another RPV resistance pathway based on K101P 
[18, 20]. We tested RPV and the RPV analogs 6, 7, 8, 
9, 11, 12, 13, 14, 15, 16, 17, 21, 26, and 27 against the 
mutants K101P, Y181I, and K101P/V179I (Fig.  5; Addi-
tional file  1: Table  S4). As has already been discussed, 
we previously tested these compounds against the 
Y181C mutant [21]. The K101P mutant showed a mod-
est decease in susceptibility to RPV (6.2  nM  ±  1.6) 
and the analogs 6 (2.5  nM  ±  0.92), 7 (9  nM  ±  2.3), 8 
(9.9 nM ± 2.5), 11 (2.4 nM ±  .14), 13 (18.1 nM ± 1.6), 
and 27 (4.9  nM  ±  2.2) and decreased the susceptibil-
ity above the limits of detection in our assay (>100 nM) 
for the analogs 9, 12, 14, 15, 16, 21, and 26. The Y181I 
mutant showed a small reduction in sensitivity to RPV 
(8.8 nM ± 0.12), 11 (2.4 nM ± 0.6), and 13 (1.2 nM ± .06) 
and showed a more significant loss in susceptibility to 6 
(55.3 nM ± 1), 7 (19 nM ± 2.6), 8 (74.8 nM ± 15.5), 15 
(50.2 nM ± 0.85), 16 (63.2 nM ± 9.1), 17 (78.9 nM ± 8.8), 
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and 27 (23.1 nM ± 4.5) and a greater loss of susceptibility 
(>100 nM) for 9, 12, 14, 21, and 26. This shows, in terms 
of susceptibility of the mutants to these compounds, 
that the impact of the Y181I mutation was considerably 
greater than the effect of the Y181C mutation [21]. The 
K101P/Y179I double mutant caused a minor reduction in 
susceptibility to 6 (12.6 nM ± 2.4), 11 (2.5 nM ± 0.95), 
and 27 (16.6  nM ±  0.5), a greater decrease in suscepti-
bility to RPV, 7, and 8, and a large loss of susceptibility 
(>100 nM) to 9, 12, 13, 14, 15, 16, 17, 21, and 26. As had 
been true with previous sets of NNRTI-resistant mutants, 
analog 11 was the most broadly effective in inhibiting 
the replication of this set of mutants. The K101P/Y179I 
double mutant was the first mutant we have tested that 
caused a substantial decrease in susceptibility to RPV; 
this highlights the significance of the fact that this double 
mutant does not significantly reduce the potency of 11. 
The analogs 6 and 27 were also broadly effective against 
this panel of resistant mutants.
Modeling the binding of 11 to HIV‑1 RT
Because of the improved antiviral profile of 11 versus 
the NNRTI-resistant mutants that we tested, we wanted 
to understand how it binds to HIV-1 RT, and the con-
tacts it makes in the NNRTI binding pocket (Fig. 6). We 
docked 11 in the NNRTI binding pocket using the crys-
tal structure of RPV bound to HIV-1 RT as the template 
to model the binding of 11 [28]. The interactions of 11 
with the NNRTI binding pocket are similar to the inter-
actions of RPV and the pocket, except that the 2,6-purine 
ring system of 11 resides deeper in the pocket (>1 Å). 
The benzonitrile linker amine is positioned similarly to 
the corresponding element of RPV and hydrogen bonds 
with the carbonyl of K101, while the dimethylphenyl 
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Fig. 5 Antiviral activities of RPV and the RPV analogs against mutants selected by RPV. The IC50 values for RPV and the RPV analogs against 
mutants selected by RPV were measured by using a single round infection assay. Error bars represent the standard deviations of independent 
experiments, n = 4. The IC50 values of the graph are at a maximum value of 100 nM. The IC50 value of several of the RPV analogs against the RPV 
resistant mutants were beyond the point of detection in our single round infection assay, >100 nM
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linker amine resides in the general vicinity as that of RPV 
(~1 Å away) and most likely interacts with water to form 
a hydrogen bond network with E138 of the RT p51 subu-
nit. The cyanovinyl that is attached to the dimethylphenyl 
moiety of 11 is ~0.5 Å deeper in the binding pocket than 
that of RPV (Fig.  6, purple circle), while the benzoni-
trile moiety of 11 is deeper (~1 Å) in the NNRTI binding 
pocket compared to RPV (Fig. 6, red circle). When RPV 
is modeled into the NNRTI binding pocket of RT with 
the mutations K101P and Y179I (data not shown), there 
is steric clash between pyrimidine ring of RPV and P101 
and I179. It appears that 11 avoids this clash by a slight 
bend in the central purine ring and by extending the 
cyanovinyl constituent deeper in the hydrophobic tun-
nel as well as bending, turning, and extending the ben-
zonitrile moiety towards the back of the NNRTI binding 
pocket (~2 Å).
RPV is the most recent NNRTI to be FDA-approved 
for the treatment of HIV-1 infection. It was designed 
and developed to effectively inhibit the replication of a 
number of common NNRTI-resistant mutants. RPV is 
comprised of three linked rings, and it is smaller than the 
largest compounds that can bind in the NNRTI binding 
pocket. As a consequence, it has the ability, when bound 
to mutant RTs, to undergo conformational changes and 
shifts in its binding position that allow it to bind tightly 
to both the WT and mutant forms of RT, altering its con-
formation to adapt to the changes in the geometry of the 
binding pocket. However, recent data suggest that RPV 
is susceptible to some NNRTI binding pocket muta-
tions [16–18]. We have made additional RPV analogs to 
determine whether structural changes would allow the 
new derivatives to be more effective against mutants that 
reduce the efficacy of RPV.
To evaluate the potential of our RPV analogs relative to 
RPV, the related drug ETR, and DOR, we examined anti-
viral efficacies of the compounds against a broad panel 
of NNRTI-resistant HIV-1 mutants. Most of the RPV 
analogs exhibited excellent antiviral activities against 
mutants that were selected by first generation NNR-
TIs and the new compound DOR, which is in late stage 
clinical trials [19]. In particular, most of the RPV ana-
logs displayed strong antiviral activities against mutants 
that contain E138K. More importantly, a double mutant, 
K101P/Y179I, which showed a significant drop in suscep-
tibility to RPV, remained susceptible to analog 11, dem-
onstrating that it has an antiviral profile that is broader 
that any of the NNRTIs we have tested thus far.
Different mutation can arise at position Y181, includ-
ing Y181I and Y181C. Y181C is susceptible to RPV and 
RPV analogs as previously described [21]. However, 
Y181I caused a substantial decrease in susceptibility to 
the RPV analogs, except for 11 and 13 (2.4 nM ± .6 and 
1.2 nM ±  .06, respectfully); a minor drop in susceptibil-
ity to RPV (8.8 nM ±  .12) was observed. The isoleucine 
side chain at position 181 could cause a steric clash with 
RPV and most of the RPV analogs that would prevent an 
interaction with Y183 and the cyanovinyl modification. 
This interaction is thought to compensate for the disrup-
tion of the π-π stacking interaction between the aromatic 
side chain of Y181 and the phenyl moiety of RPV (and 
most of the RPV analogs). The interaction with Y183 can 
still occur with the Y181C mutant [28].
11 has a structure that is distinct from the other RPV 
analogs. The central 2,6-purine ring system and the aryl 
amines of 11 are in a similar conformation to the cen-
tral pyrimidine ring of the parent compound RPV, as 
opposed to 12, 13, 14, 15, 16, 17, and 21, which are in a 
“flipped” conformation. In this arrangement, the cyanovi-
nyl functionality can extend deeper into the hydropho-
bic tunnel and the benzonitrile moiety can move more 
towards the back of the NNRTI binding pocket. In 
Fig. 6 RPV and compound 11 in the NNRTI binding pocket. RPV 
(maroon) and compound 11 (green) are shown bound in the HIV-1 RT 
NNRTI binding pocket; 11 was docked onto the RPV crystal structure. 
The residues shown in blue are important contacts for the binding of 
RPV and denote residues where mutations are selected by the drug. 
The residues shown in orange are important for the interaction of 
DOR with the NNRTI binding pocket; DOR selects for mutations at 
these positions. The red dashes represent hydrogen bonds between 
K101 and 11 and RPV and the hydrogen bond network between 
with water and E138 and 11 and RPV. The purple circle denotes the 
difference in the cyanovinyl binding depth between 11 and RPV, 
and the red circle shows the difference in the benzonitrile binding 
depth between 11 and RPV
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addition to the deeper binding of the aryl moieties of 11, 
relative to RPV, the overall structure and size of 11 could 
allow it (like RPV) to use its torsional flexibility in the 
NNRTI binding pocket in response to mutations in the 
NNRTI binding pocket [14, 28].
We also investigated why some of the compounds in 
the series are much less effective than RPV and 11. Dock-
ing 26 into the NNRTI binding pocket (Fig. 7) and com-
paring its binding to the binding of RPV, points to the 
importance of a hydrogen bond between the amine linker 
of the RPV analogs and the main chain carbonyl of K101 
as well as hydrogen bond network between the water 
molecule, E138 of the RT p51 subunit, and amine linker 
of RPV analogs. 27 is a promising analog that effectively 
inhibits the double mutant K101P/V179I, which has a 
reduced susceptibility to RPV. It is possible that 27 is 
effective because of the flexibility of its 2,9-purine ring 
system and the similarities in the orientation of the cen-
tral ring to RPV and 11. These two compounds, 11 and 
27, could be used as leads to generate additional modi-
fications that could improve contacts with the NNRTI 
binding pocket of WT HIV-1 RT and, more importantly, 
with mutant forms of RT.
Conclusions
The wide range of NNRTI-resistant mutants that have 
been identified shows how daunting the challenges are 
for designing new NNRTIs for the treatment of HIV-1 
infection. More and better compounds should be devel-
oped to achieve the goal of suppressing the emerging 
resistant HIV-1 mutants. One possible approach is to 
identify combinations of two NNRTIs that have non-
overlapping resistance profiles and then use them in 
combination (unpublished observations), rather than try-
ing to prepare a single compound that is effective against 
the growing array of NNRTI-resistant mutants [29]. Pre-
venting the emergence HIV-1 resistance is a much better 
and safer treatment strategy than attempting to deal with 
resistant mutants after they have been selected. How-
ever, that strategy does not mean that we should abandon 
the search for more effective compounds. NNRTIs offer 
better toxicity profiles than NRTIs and protease inhibi-
tors (PIs) [30, 31]. 11 and 27 represent a promising step 
in what should be an ongoing process for the develop-
ment of future NNRTIs. It also appears, based on what is 
now known, that DOR, or perhaps some improved DOR 
derivative, could be useful if it was given in combination 
with these RPV analogs.
Methods
Cell‑based assays
The human osteosarcoma cell line, HOS, was obtained 
from Dr. Richard Schwartz (Michigan State University, 
East Lansing, MI) and grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented 
with 5  % (v/v) fetal bovine serum, 5  % newborn calf 
serum, and penicillin (50  units/ml) plus streptomycin 
(50 µg/ml; Quality Biological, Gaithersburg, MD). Virion 
production and single-round infectivity assays were used 
to determine antiviral activity (IC50 values) of the com-
pounds as previously described [32].
Selection of NNRTI mutations in HIV‑1
HuT-CCR5 cells were maintained in RPMI 1640 medium 
(Life Technologies), 10 % fetal bovine serum (Atlanta Bio-
logicals), 100 U/ml penicillin (Life Technologies), 100 μg/
ml streptomycin (Life Technologies), 0.292 mg/ml l-glu-
tamine (Life Technologies), 0.5  μg/ml puromycin (EMD 
Millipore), and 100  μg/ml G418 (Life Technologies). 
Fig. 7 Binding of RPV and compound 26 in the NNRTI binding 
pocket. Using the crystal structure of RPV (maroon) in the NNRTI 
binding pocket as a template, 26 (green) was docked into the HIV-1 
RT NNRTI binding pocket. The residues shown in blue are important 
contacts for the binding of RPV; RPV selects for mutations at these 
residues. The residues shown in orange are important for the interac-
tion of DOR in the NNRTI binding pocket; DOR selects for mutations 
at these positions. The red circle shows where amine linker of RPV 
resides, which is a structural feature 26 lacks. Thus 26 fails to interact 
with main chain carbonyl of K101, suggesting that this interaction, 
made by RPV, is important. The purple circle highlights a hydrogen 
bond interaction between the pyrimidine of RPV and the main chain 
amide of K101, which 26 fails to make, presumably due to its lack of 
the amine linker. The red dashes also depict a hydrogen bond network 
between water and E138 and RPV and 11 of the RT p51 subunit
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HuT-CCR5 cells were infected with HIV-1LAI for 2 h at a 
multiplicity of infection of 0.1–0.01. Cells were cultured 
in the presence or absence of RPV, analog 7, or analog 
11. Viral RNA from the supernatant was isolated and 
used as template in RT-PCR assays with primers span-
ning the RT coding region. PCR product was sequenced 
to identify any RT mutations.
Vector constructs
pNLNgoMIVR-ΔEnv.LUC has been described previ-
ously [33]. The RT open reading frame was removed 
from pNLNgoMIVR-ΔEnv.LUC (digestion with SpeI 
and SalI) and inserted between the SpeI and SalI sites of 
pBluescript II KS+. Using that construct as the wild-type 
template, we prepared the following HIV-1 RT mutants 
using the QuikChange II XL (Stratagene, La Jolla, CA) 
site-directed mutagenesis protocol kit: L100I, K103N, 
Y181C, Y188L, H221Y, K103N/Y181C, G190A, G190S, 
M230L, P236L, L100I/K103N, K103N/P225H, V106A/
G190A/F227L, V106A, L234I, V106A/F227L, V106A/
L234I, V106A/F227L/L234I, E40K, D67E, K101E, V111A, 
E138K, M184I, M184V, K101E/M184I, K101E/M184V, 
E138K/M184I, E138K/M184V, K101P, Y181I, and K101P/
V179I. The following sense oligonucleotides were used 
with matching cognate antisense oligonucleotides (not 
shown) (Integrated DNA Technologies, Coralville, IA) in 
the mutagenesis: L100I, 5′-CATCCCGCAGGGATAAAA 
AAGAAAAAATCA-3′; L100I 2-103, 5′-ATACCACATCC 
CG C AG G GATTAAAAAGAATAAATC AGTA-3 ′ ; 
K103N, 5′-GCAGGGTTAAAAAAGAATAAATCAGTA 
ACAGTA-3′; Y181C, 5′-CCAGACATAGTTATCTGTCA 
ATACATGGATGAT-3′; Y188L, 5′-TACATGGATGATTT 
GCTAGTAGGATCTGACTTA-3′; H221Y, 5′-ACACCAG 
ACAAAAAATATCAGAAAGAACCTCCA-3′; G190A, 
5′-ATGGATGATTTGTATGTAGCATCTGACTTAG 
AAATAGGG-3′; G190S, 5′-ATGGATGATTTGTATGTA 
AGTTCTGACTTAGAAATAGGG-3′; P225H, 5′-AAAA 
AACATCAGAAAGAACATCCATTCCTTTGGATG 
GGT-3′; F227, 5′-CATCAGAAAGAACCTCCATTACTT 
TGGATGGGTTATGAA-3′; M230L, 5′-GAACCTCCAT 
TCCTTTGGCTGGGTTATGAACTCCATCCT-3 ′ ; 
P236L, 5′-ATGGGTTATGAACTGCATCTCGATAAAT 
GGACAGTACAG-3′; V106A, 5′-AAAAAGAAAAAATC 
AGCAACAGTACTGGATGTG-3′; L234I, 5′-TTCCTTT 
GGATGGGTTATGAAATCCATCCTGATAAATG 
GACAGTA-3′; E40K, 5′-GAAATTTGTACAAAAATGG 
AAAAGGAAGGG-3′; D67E, 5′-GCCATAAAGAAAAAA 
GAAAGTACTAAATGGAGA-3′; K101E, 5′-CATCCCG 
CAGGGTTAGAAAAGAAAAAATCAGTAACA-3′; 
V111A, 5′-GTAACAGTACTGGATGTAGGTGATGCAT 
ATTTTTCA-3′; E138K, 5′-CCTAGTATAAACAATAAG 
ACACCAGGGATTAGA-3′; M184I, 5′-GTTATCTATCA 
ATACATAGATGATTTGTATGTA-3′; M184V, 5′-GTTA 
TCTATCAATACGTTGATGATTTGTATGTA-3′; K101P, 
5′-CCACATCCCGCAGGGTTACCAAAGAAAAAA 
TCAGTAACA-3′; Y181I, 5′-AATCCAGACATAGTTATC 
ATTCAATACATGGATGATTTG-3′; K101P/V179I, 
5′-AAACAAAATCCAGACATAATCATCTATCAATA 
CATGGAT-3′. The double mutants K103N/Y181C, 
K103N/P225H, and L100I/K103N were made using the 
previously generated K103N mutant and the appropri-
ate oligonucleotides to add the second mutation, Y181C, 
P225, and L100I respectively. The double mutants 
V106A/F227L and V106A/L234I were prepared using the 
previously generated V106A mutant and the appropri-
ate oligonucleotides to add the second mutation, F227L 
and L234I, respectively. The double mutants K101E/
M184I and K101E/M184V were constructed using the 
previously generated K101E mutant and the appropri-
ate oligonucleotides to add the second mutation, M184I 
and M184V, respectively. The double mutants E138K/
M184I and E138K/M184V were constructed using the 
previously generated E138K mutant and the appropri-
ate oligonucleotides for the second mutation, M184I and 
M184V, respectively. The triple mutant V106A/F227L/
L234I was made using the previously generated V106A/
F227L double mutant and the appropriate oligonucleo-
tides for the third mutation, L234I. The triple mutant 
V106A/G190A/F227L was constructed in a series of 
steps using the previously generated V106A mutant and 
the appropriate oligonucleotides for the second muta-
tion, G190A, to generate the double mutant V106A/
G190A, and then the triple mutant was made using dou-
ble mutant V106A/G190A and oligonucleotides for the 
third mutation, F227L. The DNA sequence of each con-
struct was verified by DNA sequence determination. 
The sequences encoding the mutant RTs were then sub-
cloned into pNLNgoMIVR-ΔEnv.LUC (between the KpnI 
and SalI sites) to produce the mutant HIV-1 constructs. 
These DNA sequences were also checked independently 
by DNA sequence determination.
Computer modeling
All computer modeling was performed using 
MOE2014.09 (Chemical Computing Group, Montreal, 
Quebec, Canada). The previously reported crystal struc-
ture of WT HIV-1 RT/RPV complex (PDB ID: 2ZD1; 
[28]) was used in the docking stimulation to model the 
RPV analogs in the NNRTI binding pocket. The docking 
simulation used a rigid receptor protocol and refinement 
to predict the pose of the RPV analogs in the NNRTI 
binding pocket. We also used an induced fit docking pro-
tocol and refinement that permits the sidechains of the 
NNRTI binding pocket to move to determine whether 
this would affect predicted binding of the RPV analogs in 
the NNRTI binding pocket. No new poses were detected.
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